MENU
+Compare
PRME
Stock ticker: NASDAQ
AS OF
Jul 18, 04:59 PM (EDT)
Price
$4.13
Change
+$0.23 (+5.90%)
Capitalization
524.53M

PRME Prime Medicine Forecast, Technical & Fundamental Analysis

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing... Show more

PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PRME with price predictions
Jul 17, 2025

PRME's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for PRME moved out of overbought territory on July 15, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 instances where the indicator moved out of the overbought zone. In of the 8 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 28 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PRME broke above its upper Bollinger Band on July 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in of 130 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 39 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.907) is normal, around the industry mean (17.995). P/E Ratio (0.000) is within average values for comparable stocks, (59.169). PRME's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.515). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (126.582) is also within normal values, averaging (275.695).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PRME is expected to report earnings to rise 7.50% to -43 cents per share on August 06

Prime Medicine PRME Stock Earnings Reports
Q2'25
Est.
$-0.43
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.18
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.03
The last earnings report on May 08 showed earnings per share of -40 cents, beating the estimate of -43 cents. With 3.59M shares outstanding, the current market capitalization sits at 524.53M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
21 Erie Street
Phone
+1 617 564-0013
Employees
234
Web
https://www.primemedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIECX12.23N/A
N/A
Saratoga International Equity C
SUIIX58.10N/A
N/A
DWS CROCI International Inst
FAMRX29.00N/A
N/A
Fidelity Asset Manager 85%
TRMVX27.08N/A
N/A
SEI Large Cap Value F (SIMT)
ABCEX9.36N/A
N/A
AB Emerging Markets Multi-Asset C

PRME and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.47%
CRSP - PRME
63%
Loosely correlated
-0.09%
BEAM - PRME
56%
Loosely correlated
+1.89%
RXRX - PRME
56%
Loosely correlated
+5.75%
CRBU - PRME
53%
Loosely correlated
N/A
CCCC - PRME
51%
Loosely correlated
+7.92%
More